Mapi Pharma
Ness Ziona, Israel· Est.
Israeli biotech developing long‑acting depot injectables for neurology and pain.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Israeli biotech developing long‑acting depot injectables for neurology and pain.
NeurologyPainEpilepsyPsychiatry
Technology Platform
Proprietary long‑acting depot injectable formulations combined with in‑house GMP API synthesis and sterile fill‑and‑finish capabilities.
Opportunities
Successful approval of the once‑monthly GA Depot could capture a sizable share of the MS market and open pathways for additional LCM products across neurology and psychiatry.
Risk Factors
Clinical trial outcomes, regulatory approval timelines, and competition from established MS therapies pose significant execution risks.
Competitive Landscape
Key competitors include Teva’s Copaxone and Biogen’s MS portfolio; Mapi differentiates through monthly depot dosing and integrated manufacturing that reduces cost and improves patient adherence.